Zepp Health (NYSE:ZEPP) CFO Sells $45,343.96 in Stock

Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) CFO Cheng Deng sold 9,836 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $4.61, for a total transaction of $45,343.96. Following the completion of the transaction, the chief financial officer directly owned 114,539 shares in the company, valued at $528,024.79. The trade was a 7.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zepp Health Stock Performance

NYSE ZEPP opened at $4.53 on Monday. Zepp Health Corporation Sponsored ADR has a 52-week low of $2.50 and a 52-week high of $61.85. The company has a fifty day moving average of $9.78 and a 200-day moving average of $17.13. The company has a market capitalization of $66.43 million, a P/E ratio of -1.80 and a beta of 1.78. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.67 and a current ratio of 0.88.

Institutional Investors Weigh In On Zepp Health

Institutional investors and hedge funds have recently modified their holdings of the stock. FIL Ltd bought a new stake in shares of Zepp Health during the 4th quarter valued at about $16,858,000. Millennium Management LLC bought a new stake in shares of Zepp Health during the third quarter valued at approximately $11,265,000. UBS Group AG grew its stake in Zepp Health by 16,412.0% in the third quarter. UBS Group AG now owns 181,302 shares of the company’s stock worth $8,300,000 after purchasing an additional 180,204 shares during the period. Monolith Management Ltd purchased a new stake in Zepp Health in the fourth quarter worth $3,601,000. Finally, State Street Corp bought a new position in Zepp Health in the fourth quarter worth $3,421,000. 52.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZEPP. Wall Street Zen cut Zepp Health from a “hold” rating to a “sell” rating in a report on Saturday. Fundamental Research set a $56.28 price objective on shares of Zepp Health and gave the stock a “buy” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Zepp Health presently has a consensus rating of “Hold” and an average target price of $56.28.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.